Rezolute recently announced topline data from its Phase 2 study of RZ402 in patients with diabetic macular edema. We look forward to learning more about their plans to support further development of RZ402, as XOMA holds a low single-digit royalty interest in this oral kallikrein inhibitor. Rezolute, Inc. #RZ402 #DME #Diabetes #MacularEdema #DiabeticMacularEdema #Royalty #Royalties
Today we announced positive topline data from our Phase 2 study of RZ402 in patients with diabetic macular edema (DME). Check out the press release to learn more: https://bit.ly/3VbpXzi